Skip to main content
Search
Search
Advanced Search
Skip main navigation
Free access
Industry Update
4 May 2022

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 7

Authors: Alex Simpson and Sreeram V Ramagopalan [email protected]Author Info & Affiliations
Volume 11, Number 10
https://doi.org/10.2217/cer-2022-0071
PDFFormats

Abstract

This month we focus on papers that provide insights into the potential for target trial emulation to be used in health technology assessment, the role of real-world evidence (RWE) in informing additional elements of value and the importance of RWE to European joint clinical assessments.

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

1.
Gomes M, Latimer N, Soares M et al. Target trial emulation for transparent and robust estimation of treatment effects for health technology assessment using real-world data: opportunities and challenges. Pharmacoeconomics (2022) (Epub ahead of print).
Crossref
Google Scholar
2.
Brooke A, Bregman C, Dawoud D et al. In: CHTE Methods Review. Sources and Synthesis of Evidence. Task and Finish Group Report. National Institute for Health and Care Excellence,Sheffield, UK (2020).
Google Scholar
3.
National Instituate of Health and Care Excellence. NICE real-world evidence framework (draft). (2022). www.nice.org.uk/Media/Default/About/what-we-do/Real-world-evidence/RWE-framework-consultation-framework.docx
Google Scholar
4.
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology - version 9. www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml
Google Scholar
5.
Haute Autorité de santé (HAS) - Methodological guide - Real-world studies for the assessment of medicinal products and medical devices. www.has-sante.fr/upload/docs/application/pdf/2021-06/real-world_studies_for_the_assessment_of_medicinal_products_and_medical_devices.pdf
Google Scholar
6.
Neumann PJ, Garrison LP, Willke RJ. The history and future of the “ISPOR value flower”: addressing limitations of conventional cost–effectiveness analysis. Value Health 25(4), 558–565 (2022).
PubMed
Google Scholar
7.
Li M, Basu A, Bennette CS, Veenstra DL, Garrison LP. Do cancer treatments have option value? Real-world evidence from metastatic melanoma. Health Econ. 28(7), 855–867 (2019).
PubMed
Google Scholar
8.
Drummond M, Tarricone R, Torbica A. European union regulation of health technology assessment: what is required for it to succeed? Eur. J. Health Econ. (2022) (Epub ahead of print).
Crossref
Google Scholar
9.
Welton NJ, Phillippo D, Owen R et al. In: CHTE2020 Sources and Synthesis of Evidence: Update to Evidence Synthesis Methods. NICE Decision Support Unit, Sheffield, UK, 98 (2020).
Google Scholar
|